for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

DexCom, Inc.

DXCM.O

Latest Trade

423.03USD

Change

4.74(+1.13%)

Volume

641,459

Today's Range

407.62

 - 

424.28

52 Week Range

305.63

 - 

456.23

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
418.29
Open
418.29
Volume
641,459
3M AVG Volume
16.04
Today's High
424.28
Today's Low
407.62
52 Week High
456.23
52 Week Low
305.63
Shares Out (MIL)
96.71
Market Cap (MIL)
40,451.10
Forward P/E
185.29
Dividend (Yield %)
--

Next Event

Q2 2021 DexCom Inc Earnings Release

Latest Developments

More

Dexcom Inc Posts Q1 Non-GAAP Earnings Per Share $0.33

Dexcom Reports Q4 And Fiscal Year 2020 Financial Results

Dexcom Reports Preliminary, Unaudited Revenue For Q4

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About DexCom, Inc.

Dexcom, Inc. is a medical device company. The Company is primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for use by people with diabetes and by healthcare providers. Its products include Dexcom G6 and Dexcom Share. The G6 is a CGM system that can be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. Its Dexcom Share remote monitoring system, offered for use with its Dexcom system, uses an app on the patient’s iPhone, iPod touch, iPad or Android mobile device to securely and wirelessly transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients, who can remotely monitor a patient’s glucose information and receive alert notifications.

Industry

Medical Equipment & Supplies

Contact Info

6340 Sequence Dr

SAN DIEGO, CA

92121-4356

United States

+1.858.2000200

https://www.dexcom.com/

Executive Leadership

Kevin R. Sayer

Chairman of the Board, President, Chief Executive Officer

Jereme M. Sylvain

Chief Financial Officer, Executive Vice President

Quentin S. Blackford

Chief Operating Officer

Sadie M. Stern

Chief Human Resource Officer, Executive Vice President

Jacob Steven Leach

Executive Vice President, Chief Technology Officer

Key Stats

1.64 mean rating - 22 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

1.0K

2019

1.5K

2020

1.9K

2021(E)

2.3K
EPS (USD)

2018

0.300

2019

1.840

2020

3.100

2021(E)

2.257
Price To Earnings (TTM)
80.67
Price To Sales (TTM)
19.96
Price To Book (MRQ)
21.25
Price To Cash Flow (TTM)
68.68
Total Debt To Equity (MRQ)
91.58
LT Debt To Equity (MRQ)
91.58
Return on Investment (TTM)
17.45
Return on Equity (TTM)
15.03

Latest News

Latest News

BRIEF-Dexcom Prices Offering Of Upsized $1.05 Billion Of 0.25% Convertible Senior Notes

* DEXCOM PRICES OFFERING OF UPSIZED $1.05 BILLION OF 0.25% CONVERTIBLE SENIOR NOTES

BRIEF-Dexcom Reports Proposed Offering Of $850.0 Million Of Convertible Senior Notes

* DEXCOM ANNOUNCES PROPOSED OFFERING OF $850.0 MILLION OF CONVERTIBLE SENIOR NOTES

BRIEF-Health Canada Temporarily Authorizes Dexcom G6 Cgm For Use In Hospitals

* HEALTH CANADA TEMPORARILY AUTHORIZES DEXCOM G6 CGM FOR USE IN HOSPITALS TO MONITOR CRITICALLY ILL PATIENTS DURING COVID-19 PANDEMIC Source text for Eikon: Further company coverage:

BRIEF-DexCom Reports Q1 2020 Financial Results

* Q1 REVENUE $405.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $358 MILLION

BRIEF-Dexcom And Insulet Announce Commercial Agreement

* DEXCOM AND INSULET ANNOUNCE COMMERCIAL AGREEMENT TO INTEGRATE THE DEXCOM G6 AND FUTURE G7 CGM INTO INSULET’S OMNIPOD HORIZON AUTOMATED INSULIN DELIVERY SYSTEM Source text for Eikon: Further company coverage:

BRIEF-Dexcom Reports Q4 Earnings Per Share $1.00

* DEXCOM REPORTS FOURTH QUARTER AND FISCAL YEAR 2019 FINANCIAL RESULTS

CORRECTED-Dexcom says diabetes monitoring software malfunctioning since Saturday

Dexcom Inc, which makes continuous glucose monitoring systems that can be used by adults to track sugar levels in children with diabetes, said on its website Sunday that some users of a monitoring software called Dexcom Follow were not receiving data or alerts as intended.

Diabetes care firm Dexcom loses bid to narrow AgaMatrix's patent case

Diabetes management company DexCom Inc on Wednesday lost a bid to narrow a patent infringement case brought against it by rival WaveForm Technologies Inc, a subsidiary of AgaMatrix Holdings LLC.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up